A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2022-05-29
Target enrollment:
Participant gender:
Summary
This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and
pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or
recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as
combination therapy with ABBV-181 in participants with advanced solid tumors.